15 April 2025 Argent BioPharma Ltd.
[...]
This is an abstract of the document. To keep reading, click here and get access to the original version.
Strategic Agreement to Enhance Cannabinoid Development
Earlier from Argent Biopharma
- Strategic Collaboration Agreement for Malta Facility
- CannEpil Receives Approval for Prescription in Germany
- CimetrA Phase IIb Clinical Trial Results
- Argent BioPharma Expands Pipeline with Promising Drug CimetrA®
- Exclusive Agreement for Malta Manufacturing Facility
Later from Argent Biopharma
- Argent BioPharma Enters Germany - Europe's Largest Market
- EU-GMP Cannabinoid API Supplied for Epilepsy in Slovenia
- RGT Signs Binding Term Sheet to Acquire AusCann Assets
- U.S. In Vivo Study Supports ArtemiC Efficacy
- Argent is Growing Through M&A: Projected Merged Company Value of $100M in AC8 Asset Acquisition
Follow Argent Biopharma into a list and get an email when it puts out news.
Follow Argent Biopharma